Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialClaudia M. Denkinger, Michaël Schmitt, Albrecht Leo et al.|medRxiv|2022Cited by 4
S282: A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSIONC. Müller-Tidow, Claudia M. Denkinger, Maike Janssen et al.|HemaSphere|2022Cited by 2